and the Hill coefficients were the same, suggesting that these compounds act at the sulmazole site on the Ca2+-release channel.
Introduction
The main pathway for the release of intracellular Ca2 in cardiac muscle cells is the sarcoplasmic reticulum (SR) channel. The open probability (P.) of the Ca2+-release channel is modulated primarily by the concentration of Ca2+ on the cytosolic face of the channel. It is also affected by various secondary agents such as adenosine and ATP (Smith et al., 1985; McGarry & Williams, 1994) , caffeine (Rousseau et al., 1986; Sitsapesan & Williams, 1990) and anthraquinones (Holmberg & Williams, 1990b; Pessah & Zimanyi, 1991) , some of which may act independently of activating Ca2+. Ryanodine and ruthenium red act to modify singlechannel conductance and to cause channel closure, respec- tively (Meissner & Henderson, 1987 demonstrated that therapeutically relevant concentrations of cardiac glycosides increase the PO of the cardiac Ca2"-release channel in a Ca2"-dependent manner, an effect which may underlie part of the positive inotropic effect of these drugs, providing further evidence for the role of the Ca2+-release channel in excitation-contraction coupling (McGarry & Williams, 1993a) . Williams & Holmberg (1990) have shown that the caffeine analogue, (+)-sulmazole, activates the Ca2"-release channel by both a Ca2"-dependent and a Ca2"-independent mechanism and that there is a synergistic action of Ca2" and sulmazole on single-channel activity. Sulmazole isomers and several structurally related compounds (including caffeine) appear to exert similar effects in the cell. They increase the sensitivity of the contractile proteins to Ca2" (Blinks & Endoh, 1984) , inhibit type III phosphodiesterase and inhibit '." Macmillan Press Ltd, 1994 the sarcolemmal Na+/K' ATPase (van Meel et al., 1988; Honerjager et al., 1989) . Sulmazole has also been shown to be an adenosine Al antagonist and to be a functional antagonist of an inhibitory G-protein (Parsons et al., 1988) . All of these effects may contribute to the cardiotonic actions of these drugs. Van Meel et al. (1988) showed that (+)-and (-)-sulmazole were equipotent in their ability to inhibit adenosine 3':5'-cyclic monophosphate (cyclic AMP) and guanosine 3':5'-cyclic monophosphate (cyclic GMP) phosphodiesterase (PDE) but that the (+)-isomer was a more potent Ca2"-sensitizing agent, a more potent inhibitor of the Na+/K' ATPase and a more potent inotropic compound (see Figure 1 for structures). They concluded that the increased myofibrillar sensitivity to Ca2`induced by (+)-sulmazole underlay its increased inotropic effect. This would appear to suggest that the configuration of the methyl and oxygen groups around the sulphur atom of sulmazole mediate the increased potency of the compound over its (-)-enantiomer.
The effects on cardiac function of some of the sulmazole analogues used in this study were examined by Honerjager et al. (1989) . In their study, they found that the position of the pyridine nitrogen (4,5b in sulmazole and EMD46512 and 4,5c in isomazole and EMD 4100), was crucial for inhibition of the sarcolemmal Na+/K+ ATPase, since EMD 41000 and isomazole had little inhibitory activity. The presence of a methylsulphinyl oxygen also affected the ability of each compound to inhibit this enzyme, as sulmazole was approximately forty times less potent than its reduced analogue EMD 46512. The pyridine nitrogen position also affected the inhibition of type III PDE, as isomazole and EMD 41000 were approximately two and three times as potent as EMD 46512 and sulmazole, respectively. The reduced analogues were slightly more potent inhibitors of type III PDE than Sulmazole Figure 1 The structures of sulmazole and its reduced analogue, EMD 46512. The position of the chiral sulphur atom is highlighted in sulmazole. The difference between sulmazole and isomazole is the position of the pyridine nitrogen. Its position in isomazole and its reduced analogue EMD 41000 is shown by the arrow. The benzimidazole numbering system is used. In the lower part of the figure, the position of the asymmetry in sulmazole is shown. their respective oxidised parent compounds. Not surprisingly, the reduced analogue EMD 46512 was found to be a more potent cardiotonic drug than sulmazole.
The effects of these compounds on the cardiac SR Ca2+-release channel, with the exception of (+)-sulmazole, have not been directly investigated. An investigation of their action on the channel may help elucidate the structural features of compounds that are responsible for activity at the caffeine/sulmazole site on the release channel and may also shed light on a new action of these drugs in cardiac muscle cells.
A preliminary account of this work has been presented to the British Pharmacological Society (McGarry & Williams, 1993b) .
Methods

Preparation of SR membrane vesicles
The membrane preparation was as described by Sitsapesan & Williams (1990) . Fresh sheep hearts were obtained from the abattoir and transported to the laboratory in cold modified cardioplegic solution (Tomlins et al., 1986) . Approximately 100 g of left ventricle and septum were homogenized in a solution containing 300 mM sucrose, 20 mM potassium piperazine-N'N'-bis-ethanesulphonic acid (PIPES) and 1 mM phenylmethanesulphonyl chloride (PMSF), pH 7.4. The homogenate was centrifuged at 8000 gav in a Sorvall GSA rotor for 20 min at 4°C. The supernatant was centrifuged at 100,000 gav in a Sorvall T647.5 rotor for 40 min. The resulting membrane pellet was resuspended in a solution containing (mM):
KCl 400, MgCl2 0.5, CaCl2 0.5, 1,2-di(2-aminoethoxy)ethane-N,N,N',N'-tetraacetic acid (EGTA) 0.5, PIPES 25 and 10% w/v sucrose, pH 7.0. The membrane suspension was layered onto identical salt solutions containing 20, 30 and 40% w/v sucrose and centrifuged at 100,000gav for 120 min in a Sorvall AH-629 rotor at 4°C. Heavy SR (HSR) membrane vesicles collecting at the 30-40% interface were diluted into 400 mM KCl and pelleted by centrifugation at 100,000 gav for 40 min in a Sorvall T647.5 rotor before resuspension in a solution containing 400 mM sucrose, 5 mM N'-2-hydroxyethylpiperazine-N'-2-sulphonic acid (HEPES) titrated to pH 7.4 with tris(hydroxymethyl)-methylamine (Tris). Membrane vesicles were snap frozen in liquid nitrogen and stored at -80°C.
Single-channel methods
Lipid bilayers containing phosphatidylethanolamine in decane (30 mg ml-') were formed across a 200 lim diameter hole in the partition between two fluid-filled styrene copolymer chambers, referred to as cis and trans. The trans chamber was held at ground and the cis chamber clamped at holding potentials relative to this. Current flow through the bilayer was measured with an operational amplifier as a current-voltage converter (Miller, 1982) . Initially, both chambers contained 50 mM choline chloride, 10 mM HEPES and 5 mM CaC12, with the pH adjusted to 7.4 with Tris. HSR vesicles were added to the cis chamber. The chamber was stirred and the choline chloride concentration increased to give a 7:1 gradient cis-trans to promote vesicle fusion with the bilayer, fusion being marked by the appearance of C1--selective channels (Smith et al., 1985 displayed in non-cumulative histograms. Individual lifetimes were fitted to a probability density function using the method of maximum likelihood (Colquhoun & Sigworth, 1983) . Lifetimes lasting less than 1 ms were incompletely resolved under these data acquisition conditions and were therefore excluded from the fitting procedures. A missed events correction was applied (Colquhoun & Sigworth, 1983 ) and a likelihood ratio test was used to compare fits to double and triple exponentials (Blatz & Magleby, 1986) .
Single-channel conductance was obtained from the slope of the linear regression lines drawn through single-channel current amplitude data monitored at holding potentials within the range (+ 40 to -40 mV). Reversal potentials were obtained from extrapolations of these lines. The Ca2+/Tris+ permeability ratio was calculated from the equation given by Fatt & Ginsborg (1958) .
Binding assay Binding of [3H]-ryanodine to HSR membranes was conducted essentially as described by Holmberg & Williams (1990a) . For equilibrium binding, HSR membranes (100 ljg protein) were incubated with 1 nM [3H]-ryanodine (76 Ci mmol ') for 90 min at 37°C in a solution containing 1 M KCl and 25 mM PIPES, pH 7.4, in a final volume of 1 ml. The appropriate analogue was added at the beginning of the assay. Non-specific binding was determined by the addition of 1 g4M unlabelled ryanodine. Binding was terminated by the addition of 5 ml ice cold binding buffer followed by immediate filtration through a Whatman GF/B filter pre-soaked in binding solution. The filter was then washed with three further 5 ml volumes of buffer before being placed in 1Oml
Packard MV scintillant and the remaining radioactivity on the filter counted in a liquid scintillation counter.
The data points from each single-channel and binding experiment for each drug were averaged and are displayed graphically as the mean ± standard error of the mean. The data were fitted to a four parameter logistic equation using INPLOT4 (GraphPad Software):
where A is the bottom of the curve; B is the maximum, constrained to 1; c is the log EC%; d is the Hill slope; and x is the ligand concentration.
Molecular modelling of drug structures
The structures of the different sulmazole analogues and also caffeine were modelled using the molecular modelling package HyperChem (release 3 for Microsoft Windows), from Autodesk Inc. on a Viglen 486 DX33. The structures were built and minimized in the MM + force field using the Fletcher-Reeves algorithm (conjugate gradient method). The minimized structures were compared to those obtained using the Polak-Ribiere algorithm, to ensure a minimum had been reached, and in all cases were found to be identical. The activation of the channel by (+)-sulmazole has been described by Williams & Holmberg (1990) . This enantiomer was also able to increase the P0 of single channels and this Figure 5 ) and 465 AM (n = 4) for (-)-sulmazole. The Hill slope for the activation was approximately two for both drugs, suggesting that at least two molecules bind to the Ca2+-release channel. Both enantiomers displayed the ability to cause almost maximal activation of the channel in the presence of submaximally activating Ca2+ (10 JM) and the responses showed no signs of desensitization or fade, even over periods in excess of 20 min.
Drugs (+)-and (-)-
The position of the nitrogen in the pyridine ring is unimportant for activation of the Ca2+-release channel
The structurally-related compounds (+)-and (-)-isomazole, which differ from the sulmazole isomers in the position of the pyridine nitrogen (4,5b in sulmazole; 4,5c in isomazole), also dose-dependently increased the PO of single Ca2"-release channels in the presence of 10JM activating Ca2". Figure 4 shows the increase in single-channel P0 induced by (+ )-isomazole. In common with the sulmazole compounds, the activation occurred when the drugs were added to the cyto- (Figure 6) . Similarly, the reduced isomazole analogue, EMD 41000, was as potent as EMD 46512, with an EC50 of 40 pM (n = 5).
In comparison to its parent compounds it is also approximately ten times as potent (Figure 7) .
None of the sulmazole congeners affected the single Ca +-release channel conductance at 10 EM Ca2`(90 ± 3 pS ( ± s.e. mean), n = 7) or the Ca2+/Tris' permeability ratio (12.8 + 0.2, n = 7). These values are similar to those obtained by Williams & Holmberg (1990) . The PO of channels activated by any of the sulmazole analogues in the presence of activating Ca2+ was decreased by the addition of ruthenium red or Mg2" (not shown).
Ca2+-independent activation of the Ca2+-release channel by sulmazole analogues
All of the sulmazole analogues tested were able to increase the open probability of SR Ca2"-release channels at subactivating Ca2" concentrations. In the effective absence of cytosolic Ca2" (pM Ca2") the Ca2"-release channel is closed. Figure 8 Site of action in relation to caffeine The action of caffeine on cardiac SR Ca2"-release channel PO has been studied previously by Rousseau & Meissner (1989) and Sitsapesan & Williams (1990) . Their results showed that the mechanism by which caffeine increases single-channel PO is similar to that demonstrated here and by Williams & Holmberg (1990) The data obtained with both these sets of isomers also demonstrate that the position of the nitrogen in the pyridine ring, either in the 4,5b or 4,5c position, does not affect the potency of these drugs in activating the Ca2"-release channel.
The change in the position of the pyridine nitrogen changes the electron density in the ring system. As this has no effect, this may suggest that the nitrogen atom in the 4,5b or 4,5c positions in the pyridine ring in these compounds does not play a significant role in the binding of these compounds to their sites on the channel protein.
That there is no stereoselectivity at the sulmazole activation site together with our demonstration that the position of the pyridine nitrogen is unimportant for the activation of the Ca2"-release channel by these analogues is in contrast to the situation with the sensitization of the myofilaments to Ca2" and the inhibition of the Na+/K' ATPase and type III PDE by these compounds. Van Meel et al. (1988) showed that (+)-sulmazole was a more potent Ca2+-sensitizing agent than its (-)-enantiomer. Also, Honerjager et al. (1989) found that sulmazole compounds were more potent inhibitors of the ATPase and that isomazole compounds were slightly more potent PDE inhibitors. It could have been suggested that these analogues were binding to type III PDE which are known to be present in SR membranes (Kauffman et al., 1989; Lugnier et al., 1993) , thereby modulating Ca2+-release channel Po. However, as the pharmacology of these compounds in activating the SR Ca2`-release channel is different Ca2" is present, the binding of a second drug molecule is stimulated, and the presence of two molecules of activating drug together with Ca2" allows full channel activation. This shows that there is a Ca2t-dependent and a Ca2"-independent action of these drugs to increase the P. of the Ca2"-release channel.
The differences in the structures of the sulmazole and isomazole enantiomers reside in the orientation of the double-bonded oxygen atom and the methyl group around the terminal sulphur atom, the sulphur being a chiral centre. As the enantiomers are mirror images of each other it can be estimated that the oxygen in each protrudes 0.825A above or below the plane of the molecule (which is flat) and the carbon of the methyl group protrudes 1.715A above or below the plane. The reduced analogues, EMD46512 and EMD 41000, are devoid of a double bonded oxygen attached to the sulphur and the remaining methyl group reorientates into the plane of the molecule. As these drugs are approximately ten times as potent as their respective parent compounds, it is possible that the presence of this oxygen in sulmazole and isomazole hinders the binding of the compounds to the Ca2+-release channel. The lack of the physical bulk or lack of charge due to the oxygen may thus allow the reduced analogues better access to their sites, resulting in increased potency of the reduced compounds. However, it is also a possibility that the protruding methyl group in sulmazole or isomazole may similarly hinder proper access to binding sites and contribute to the lack of potency of these drugs in comparison to the reduced analogues. Regardless of this uncertainty, it is apparent that minor modifications around the sulphur atom dramatically affect potency, suggesting that the area around the sulphur may be critically involved in the channel activation. Further modifications in the area around this atom may result in drugs with greater ability to activate the Ca2"-release channel or even antagonists of the compounds studied here. Notwithstanding this, it is not unreasonable to suggest that modifications at other points in the molecule may also affect the potency of the compound.
Modelling of the structures of the analogues used in this study and caffeine show that the imidazopyridine ring of the sulmazole analogues can be directly superimposed on the purine ring of caffeine. As these compounds exert similar effects by similar mechanisms (albeit with different potencies) on the SR Ca2+-release channel, it is possible that they act by binding to the same sites on the channel protein. As the caffeine site on the channel has been demonstrated to be distinct from the adenosine sites (McGarry & Williams, 1993a) this suggests that adenosine and sulmazole also act at different sites on the channel. If the sulmazole analogues and caffeine act at the same sites on the Ca2"-release channel then this suggests that although substituents in the area around the sulphur atom of the sulmazole compounds may influence potency, the imidazopyridine ring of the drugs is also involved in their binding to the protein.
In conclusion, this study shows that several analogues of sulmazole increase the P0 of the cardiac SR Ca2"-release Supported by the British Heart Foundation.
